Raymond James & Associates Lineage Cell Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 23,437 shares of LCTX stock, worth $14,999. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,437
Previous 25,726
8.9%
Holding current value
$14,999
Previous $25,000
16.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$26.7 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$5.5 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$3.2 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$3.2 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $109M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...